Skip to main content

Advertisement

SpringerLink
Log in

Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men

  • Research Article
  • Published:
Tumor Biology

Abstract

This study aims to evaluate the relationship between the cyclooxygenase 2 (COX2) G1195A (rs689465) polymorphism and the risk of prostate cancer in a Japanese population and the associations between COX2 polymorphisms and clinicopathological characteristics, including Gleason grade and prostate-specific antigen (PSA) grade. We recruited 134 patients with prostate cancer and 86 healthy controls matched for age and smoking status. The COX2 G1195A polymorphism status was determined by polymerase chain reaction and restriction fragment length polymorphism analysis. Genotype distributions (p = 0.028) and allelic frequencies (p = 0.014) differed significantly between prostate cancer and control groups in terms of the COX2 G1195A polymorphism (Pearson’s χ 2 test). Logistic regression analysis of case and control outcomes showed an odds ratio between the GG and AA genotypes of 3.15 (95 % confidence interval = 1.27–8.08, p = 0.014), indicating an increased risk of prostate cancer associated with the AA genotype. Subset analysis revealed no significant associations between this polymorphism and clinicopathological characteristics of prostate cancer. This study demonstrated a relationship between the COX2 G1195A variant and prostate cancer risk. This polymorphism may merit further investigation as a potential genomic marker for the early detection of prostate cancer. Our results support the hypothesis that rs689465 influences susceptibility to prostate cancer; however, prostate cancer progression was not associated with rs689465 in a Japanese population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Committee for Establishment of the Guidelines on Screening for Prostate Cancer. Japanese Urological Association: updated Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int J Urol. 2010;17(10):830–8.

    Article  CAS  Google Scholar 

  2. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217–26.

    PubMed  Google Scholar 

  3. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006;77:127–9.

    Article  PubMed  CAS  Google Scholar 

  4. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205–18.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008;44:1093–9.

    Article  PubMed  CAS  Google Scholar 

  6. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 2007;137:194–9.

    Google Scholar 

  7. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta. 1995;1299:125–40.

    Article  Google Scholar 

  8. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–66.

    Article  PubMed  CAS  Google Scholar 

  9. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–73.

    PubMed  CAS  Google Scholar 

  10. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97:557–61.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004;25:961–6.

    Article  PubMed  CAS  Google Scholar 

  12. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119:668–72.

    Article  PubMed  CAS  Google Scholar 

  13. Fernandez P, de Beer PM, van der Merwe L, Heyns CF. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis. 2008;29:2347–50.

    Article  PubMed  CAS  Google Scholar 

  14. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C. 2004;129:65–73.

    Article  Google Scholar 

  15. Bau DT, Tsai MH, Huang CY, Lee CC, Tseng HC, Lo YL, et al. Relationship between polymorphisms of nucleotide excision repair genes and oral cancer risk in Taiwan: evidence for modification of smoking habit. Chin J Physiol. 2007;50:294–300.

    PubMed  CAS  Google Scholar 

  16. Chang CH, Wang RF, Tsai RY, Wu HC, Wang CH, Tsai CW, et al. Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res. 2009;29:3903–7.

    PubMed  CAS  Google Scholar 

  17. Wu GY, Hasenberg T, Magdeburg R, Bönninghoff R, Sturm JW, Keese M. Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg. 2009;33:124–9.

    Article  PubMed  Google Scholar 

  18. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42:73–8.

    Article  PubMed  CAS  Google Scholar 

  19. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005;129:565–76.

    PubMed  CAS  Google Scholar 

  20. Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A. 2007;70:908–15.

    Article  PubMed  CAS  Google Scholar 

  21. Chiang SL, Chen PH, Lee CH, Ko AM, Lee KW, Lin YC, et al. Up-regulation of inflammatory signallings by areca nut extract and role of cyclooxygenase-2 -1195G>A polymorphism reveal risk of oral cancer. Cancer Res. 2008;68:8489–98.

    Article  PubMed  CAS  Google Scholar 

  22. Peters WH, Lacko M, Te Morche RH, Voogd AC, Oude Ophius MB, Manni JJ. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck. 2009;31:938–43.

    Article  PubMed  Google Scholar 

  23. Wu HC, Chang CH, Ke HL, Chang WS, Cheng HN, Lin HH, et al. Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan. Anticancer Res. 2011;31(1):221–5.

    PubMed  CAS  Google Scholar 

  24. Mandal RK, Mittal RD. Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort. Arch Med Res. 2011;42(7):620–6.

    Article  PubMed  CAS  Google Scholar 

  25. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case–control study. Int J Cancer. 2007;121:1325–30.

    Article  PubMed  CAS  Google Scholar 

  26. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006;66:7370–7.

    Article  PubMed  CAS  Google Scholar 

  27. Wark PA, Van der Kuil W, Ploemacher J, Van Muijen GN, Mulder CJ, Weijenberg MP, et al. Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. Int J Cancer. 2006;119:398–405.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Departments of Urology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake-cho, Miyazaki, 889-1692, Japan

    Satoru Sugie, Hiromasa Tsukino, Shoichiro Mukai & Toshiyuki Kamoto

  2. Department of Urology, Fujimoto Sogo Hospital, Miyakonojo, Miyazaki, Japan

    Takahiro Akioka, Norihiko Shibata & Masafumi Nagano

Authors
  1. Satoru Sugie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiromasa Tsukino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shoichiro Mukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takahiro Akioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Norihiko Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masafumi Nagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshiyuki Kamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiromasa Tsukino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sugie, S., Tsukino, H., Mukai, S. et al. Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men. Tumor Biol. 35, 2717–2721 (2014). https://doi.org/10.1007/s13277-013-1358-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1358-y

Keywords

Search

Navigation